By Nana O 
A groundbreaking preclinical study from Weill Cornell Medicine researchers is poised to redefine our understanding of glioblastoma, one of the most aggressive and intractable forms of brain cancer. Published on April 3 in the prestigious journal Molecular Cell, the findings suggest that the intricate three-dimensional folding of DNA within the nucleus of brain cells may hold the key to developing novel therapeutic strategies. This research shifts the paradigm from a singular focus on gene mutations to a more holistic view that encompasses the spatial organization and regulatory networks of the genome.
Dr. Effie Apostolou, an associate professor of molecular biology in medicine at Weill Cornell, who co-led the study, highlighted the persistent challenges in treating glioblastoma. "Glioblastoma is one of the most aggressive and incurable tumors," Dr. Apostolou stated. "Although we know a lot about the mutations and the genes that characterize it, we still have no effective ways to stop it. Now, we’re bringing a fresh perspective to the problem. We may have a chance of figuring out the regulatory logic of this cancer and identifying potential control centers that we can target to eliminate it."
The human genome, if stretched end to end, would measure approximately six feet in length. To accommodate this vast genetic material within the microscopic nucleus of a cell – which is about 80 times smaller than a grain of sand – DNA undergoes an extraordinary process of folding and coiling. This complex three-dimensional architecture brings together DNA regions that are linearly distant, creating specialized organizational structures known as "chromatin hubs." These hubs are critical for regulating gene expression and coordinating cellular functions.
"By examining the DNA organization in the 3D space, we uncovered hubs where multiple genetic regions that look like they should be disconnected are actually able to communicate and work together," explained Dr. Apostolou. In healthy cells, these hubs are meticulously orchestrated to manage essential physiological processes, such as embryonic development. However, the Weill Cornell researchers discovered a starkly different scenario within glioblastoma cells.
Unraveling Aberrant Gene Communication in Glioblastoma
When the researchers analyzed glioblastoma cells obtained from various patients, they observed a significant deviation from normal cellular organization. Cancer-driving genes, which are often implicated in tumor formation and progression, were found to be clustered together within these 3D hubs. More alarmingly, these oncogenic hubs were also coordinating with other genes that had not previously been identified as playing a direct role in glioblastoma. This suggests a complex interplay of genetic elements, facilitated by their spatial proximity, that fuels the malignancy.
Dr. Howard Fine, the Louis and Gertrude Feil Professor of Medicine in Neurology at Weill Cornell Medicine and director of the Brain Tumor Center at NewYork-Presbyterian/Weill Cornell Medical Center, who also co-led the study, emphasized the profound implications of these findings. "This study shows that the 3D organization of DNA inside tumor cells plays a powerful role in driving brain cancer behavior — sometimes even more than mutations themselves," Dr. Fine commented. This statement underscores a fundamental shift in understanding cancer pathology, suggesting that the physical arrangement of genetic material can be as, if not more, influential than the specific genetic alterations present.
The study’s co-first authors are Dr. Sarah Breves, a surgical resident at NewYork-Presbyterian/Weill Cornell Medical Center and a member of Dr. Apostolou’s lab, and Dr. Dafne Campigli Di Giammartino from the Instituto Italiano di Tecnologia in Genova, Italy. Their contributions were instrumental in dissecting the complex molecular mechanisms at play.
The Power of 3D Gene Hubs: How Form Dictates Function
In a healthy cellular environment, the DNA regions that form these critical hubs are typically transcriptionally quiescent, meaning the genes within them are not actively being used to produce proteins that would alter cell function. This suggests a mechanism of regulation where these potentially problematic gene clusters are kept dormant in normal cells. The researchers hypothesized that disrupting these hubs in glioblastoma cells could have a significant impact on their cancerous behavior.
To test this hypothesis, the research team obtained glioblastoma cells from tumor samples of patients undergoing treatment at NewYork-Presbyterian/Weill Cornell Medical Center, with their informed consent. These patient-derived cells provided a realistic model for studying the disease.
Using a sophisticated gene-editing tool called CRISPR interference (CRISPRi), the researchers were able to precisely silence a suspected cancer-related hub within these glioblastoma cells grown in laboratory settings. The results were striking and demonstrated a cascading effect. The silencing of the hub led to a significant drop in the activity of many genes connected to it. Crucially, multiple genes known to drive cancer were disrupted, and the cancer cells exhibited a reduced ability to form tumor-like spheres – a key indicator of their tumorigenic potential.
"We were able to alter the oncogenic program of glioblastoma cells and their ability to organize and form something like cancer in the dish," Dr. Apostolou reported. This experimental validation provides compelling evidence that targeting these 3D gene hubs can directly interfere with the fundamental processes that sustain glioblastoma.
Beyond Brain Cancer: A Universal Feature of Malignancy?
The implications of these findings extend far beyond glioblastoma. The researchers expanded their investigation by examining previously published genomic analyses of 16 different types of cancer. Their analysis revealed that these hyperconnected 3D chromatin hubs are not unique to brain cancer but appear to be a prevalent feature across a wide spectrum of malignancies, including melanoma, lung cancer, prostate cancer, and uterine cancer, among others.
While each cancer type exhibits a unique set of interconnected hubs that drive its specific pathology, the study also identified shared hubs across multiple cancer types. This suggests that targeting these common hubs could potentially offer therapeutic benefits for a broad range of cancers, representing a significant advancement in oncology.
A critical aspect of the study was to understand the origins of these aberrant 3D hubs. The researchers observed that the majority of these structures are not a direct consequence of overt genetic mutations, such as DNA breaks, amplifications, or rearrangements. Instead, they frequently arise from epigenetic alterations – changes that affect how DNA is packaged and how genes are regulated without altering the underlying DNA sequence.
Specifically, the protein machinery responsible for binding to DNA sequences and controlling gene activation or silencing plays a pivotal role in the formation of these 3D hubs. These epigenetic mechanisms, which can be influenced by environmental factors and cellular processes, appear to be the primary drivers of this altered genomic architecture in cancer.
Future Therapeutic Avenues and Broader Implications
The discovery of these key control hubs within the 3D genome opens up exciting new avenues for therapeutic intervention. Dr. Fine, who also serves as the associate director for translational research at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, expressed optimism about the potential of these findings. "By identifying key control hubs in this 3D structure, we’ve uncovered new potential targets for future treatments," he stated.
The next phase of research will focus on understanding the precise mechanisms by which these hubs form and investigating whether they can be safely disrupted to impede tumor growth. The research team’s findings strongly suggest that targeting the epigenetic landscape and the spatial organization of the genome could serve as a powerful complement to existing molecular therapies.
The study’s publication in Molecular Cell marks a significant milestone in cancer research. It provides a compelling narrative that moves beyond a DNA-centric view of cancer to embrace the dynamic and spatially organized nature of the genome. This shift in perspective could lead to the development of novel diagnostic tools and therapeutic strategies that address the complex regulatory networks driving cancer, offering renewed hope for patients battling devastating diseases like glioblastoma. The implications of this research are vast, potentially paving the way for a new era of precision oncology that accounts for the intricate three-dimensional architecture of our genetic material.